Tag: ARGX

Upside

– $PROF +19% (preliminary Q3 revenue was about 45%-47% above consensus, with gross margin expected above 70%)

– $HAE +14% (no fresh company catalyst confirmed; unusually large move on light premarket volume)

– $WOLF +13% (received a conditional commitment for up to $1.5B of 30-year U.S. defense financing, partly offset by warrants for up to 7.5% of diluted equity)

– $EFX +4.5% (no fresh company catalyst confirmed; unusually large premarket move)

– $APA +3.1%, OXY +2.5%, DVN +2.4% (oil producers rise as WTI and Brent jump roughly 4.5%)

– $PLTR +2.3% (extends AI-software momentum despite weaker index futures)

– $PEP +1.6% (Q3 revenue and profit beat expectations; a better-than-feared quarter offsets a cut to the FY earnings-growth outlook)

Downside

– $ARGX -15% (Phase 3 UNITY study in Sjögren’s disease was stopped for futility, overshadowing positive Phase 2 celiac-disease data)

– $GLW -3.3% (no fresh company catalyst confirmed; unusually large premarket move)

– $EQIX -3.0% (rate-sensitive data-center REIT falls as the 10-year Treasury yield climbs to roughly 5.33%)

– $NXPI -3.1%, $AMAT -2.5%, $LRCX -2.9%, $HPE -2.0% (semiconductor and hardware names weaken as Treasury yields rise and global technology shares sell off)

– $SHW -2.7% (crude-oil surge raises petrochemical feedstock and input-cost concerns)